Abiopharma

Passage Bio Inc (PASG) Announces Clinical Trial Update Passage Bio Inc (PASG) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: period
• Diseases/Conditions: comply
• Update Type: Trial Timeline Adjustment
• Collaboration: Registrant
  • targeting infantile-onset MLD, which is characterized by progressive muscle weakness, rigidity, gait disorder, developmental delays and is typically fatal by five years of age. The estimated worldwide incidence of MLD is approximately 1 in 100,000 live births. The Phase 1 clinical trial will utilize intra-cisterna magna administration to deliver an AAVhu68 capsid to express ARSA and hopefully address both central nervous system and peripheral manifestations of this devastating disease. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934